A251120 Stock Overview
Develops active ingredients for anti-aging cosmetics in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIO-FD&C Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,300.00 |
| 52 Week High | ₩19,150.00 |
| 52 Week Low | ₩11,200.00 |
| Beta | 0.65 |
| 11 Month Change | -9.36% |
| 3 Month Change | 3.66% |
| 1 Year Change | 17.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.08% |
Recent News & Updates
Shareholder Returns
| A251120 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.7% | 3.2% | 2.9% |
| 1Y | 17.2% | 37.4% | 4.4% |
Return vs Industry: A251120 underperformed the KR Biotechs industry which returned 37.4% over the past year.
Return vs Market: A251120 exceeded the KR Market which returned 4.4% over the past year.
Price Volatility
| A251120 volatility | |
|---|---|
| A251120 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A251120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A251120's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Sang-Hyun Mo | www.biofdnc.com |
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, herbal extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, skin moisturizing, anti-inflammation/skin soothing, and anti-oxidation.
BIO-FD&C Co.,Ltd. Fundamentals Summary
| A251120 fundamental statistics | |
|---|---|
| Market cap | ₩133.04b |
| Earnings (TTM) | ₩5.81b |
| Revenue (TTM) | ₩16.06b |
22.9x
P/E Ratio8.3x
P/S RatioIs A251120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A251120 income statement (TTM) | |
|---|---|
| Revenue | ₩16.06b |
| Cost of Revenue | ₩4.89b |
| Gross Profit | ₩11.17b |
| Other Expenses | ₩5.36b |
| Earnings | ₩5.81b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 667.87 |
| Gross Margin | 69.56% |
| Net Profit Margin | 36.16% |
| Debt/Equity Ratio | 2.0% |
How did A251120 perform over the long term?
See historical performance and comparison